Katherine Nathanson

Katherine Nathanson at the Abramson Cancer Center is an expert in moderate-penetrance cancer susceptibility genes, particularly CHEK2 and ATM, which confer intermediate breast and pancreatic cancer risks. Her research has characterized the clinical implications of these variants and contributed to management guideline development for carriers. She has also studied multigene panel testing outcomes and the challenges of variant of uncertain significance interpretation.